Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04578132
Other study ID # SOG-INM-2020-04
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date November 24, 2020
Est. completion date October 2022

Study information

Verified date March 2021
Source Spanish Oncology Genito-Urinary Group
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The identification of patients with genitourinary tumors who suffer from the infection by the Serious Acute Respiratory Syndrome Corona-Virus 2 (SARS-CoV-2) virus can represent multiple benefits both for themselves and for health professionals and the health system itself. We would be able to know more precisely the clinical evolution of these type of patient, to know their prognosis and being capable to select the most appropriate treatment modality for future pandemics. SOGUG-COVID is an observational prospective-retrospective trial purely epidemiological, that aims to describe the population with genitourinary tumors (urothelial cancer, prostate cancer, testicular cancer and kidney cancer) infected by COrona VIrus Disease 19 (COVID-19) treated in Spanish hospitals, learn about the clinical presentation, therapeutic evolution and prognosis of said intercurrent infectious process, as well as its possible relationship with different clinical and therapeutic factors.


Description:

The study will be carried out in Spanish hospitals, with principal investigators belonging to the medical oncology services of the SOGUG group (Spanish Group of Genitourinary Oncology), who will act as promoter. Once the patients have been selected, the variables of interest will be collected and studied. The main variables to record will be: 1. Patient characteristics 2. Hospital center where the patient is recruited 3. Pathological history: Concomitant pathology Usual drug treatment 4. Tumor pathology: Tumor type, histology, and stage (initial and at diagnosis of infection) Cancer diagnosis date Active cancer treatment or follow-up Participation in clinical trial Type of treatment most recently received for the infection (Surgery; Radiotherapy; Chemotherapy, Immunotherapy ...) Treatment lines, initiation and last dose received of the most recent most recent cancer treatment 5. COVID-19 infection: Confirmation date of COVID-19 infection PCR (Polymerase Chain Reaction) diagnostic test Immunoglobulin G (IgG) or Immunoglobulin M (IgM) serological diagnostic test Present symptoms, analytical alterations, thrombosis associated with COVID-19 infection, complications of infection Date of onset and disappearance of symptoms Days of fever and cough Radiological examination at the time of greatest severity Treatments received for COVID-19 Status upon discharge Date of discharge / exitus Negative presence of virus by PCR and PCR date 6. For patients who are receiving or have received immunotherapy treatments, additional information will be collected: Immunotherapy treatment line and type Start / end date and last dose previous infection of the treatment with immunotherapy Adverse effects 7. Prospective follow-up data (6 months from patient inclusion): Date of start or restart of cancer treatment after infection Change / suspension of cancer treatment after COVID-19 Date of surgery in neoadjuvant patients Recurrence of COVID-19 Best response obtained Date of progression to cancer treatment Current status and date of last contact The study will use the data obtained from the patient's medical history, with no plans to use other sources. The assignment of a patient to a specific therapeutic strategy has already been decided in advance by the usual clinical practice of medicine; The decision to prescribe a specific treatment is clearly dissociated from the decision to include a patient in the study. No intervention will be applied to patients, whether diagnostic or follow-up, that is not the usual clinical practice. Epidemiological methods will be used to analyze the collected data.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 408
Est. completion date October 2022
Est. primary completion date June 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients =18 years old. - Diagnosed with genitourinary cancer (urothelial, kidney, prostate and germ). - COVID-19 infection prior to cancer treatment, during treatment, or after treatment. - The COVID-19 infection must be confirmed by PCR or serology, regardless of whether or not the patient requires hospitalization for the infection, additionally, a clinical and / or radiological determination must be available in those patients who present symptoms. Exclusion Criteria: - Not applicable

Study Design


Locations

Country Name City State
Spain Hospital Universitario de Badajoz Badajoz
Spain Hospital del Mar Barcelona
Spain Hospital Santa Creu i Sant Pau Barcelona
Spain Hospital Universitario Vall d Hebron Barcelona
Spain Hospital Universitario de Burgos Burgos
Spain Hospital de Ciudad Real Ciudad Real
Spain Hospital Universitario Reina Sofía Córdoba
Spain Instituto Catalán de Oncología- Girona Girona
Spain Institut Català d'Oncologia L'Hospitalet Hospitalet de Llobregat Barcelona
Spain Hospital Universitario Lucus Augusti Lugo
Spain Fundación Jiménez Díaz Madrid
Spain Hospital 12 de Octubre Madrid
Spain Hospital Clínico San Carlos de Madrid Madrid
Spain Hospital Infanta Leonor, Madrid
Spain Hospital Universitario Gregorio Marañón Madrid
Spain Hospital Universitario HM Sanchinarro Madrid
Spain Hospital Universitario La Paz Madrid
Spain Hospital Universitario La Princesa Madrid
Spain Hospital Universitario Quironsalud Madrid
Spain Hospital Universitario Ramón y Cajal Madrid
Spain Hospital Universitario Puerta de Hierro-Majadahonda Majadahonda Madrid
Spain Althaia Manresa Barcelona
Spain Complejo Hospitalario Universitario Ourense Orense
Spain Clinica Universidad de Navarra Pamplona
Spain Hospital Universitari Parc Taulí Sabadell Barcelona
Spain Hospital Universitario Virgen Macarena Sevilla
Spain Hospital Nuestra Señora del Prado Talavera De La Reina
Spain Hospital Virgen de la Salud Toledo
Spain Hospital Universitario Dr. Peset Valencia
Spain Instituto Valenciano de Oncología Valencia
Spain Hospital Txagorritxu Vitoria
Spain Hospital Miguel Servet Zaragoza

Sponsors (1)

Lead Sponsor Collaborator
Spanish Oncology Genito-Urinary Group

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Baseline characteristics Describe the population infected by COVID-19 with genitourinary tumors (urothelial cancer, prostate cancer, testicular cancer and kidney cancer) treated in Spanish hospitals, know the clinical presentation: Age, gender, cancer type. Categorical variables will be presented as counts and percentages. Through study completion, average 1 year
Primary Frequency of complications of COVID-19 intercurrent infection Percentage of patients with complications associated to COVID-19 infection (classified by type and severity) Through study completion, average 1 year
Primary Frequency of complications of COVID-19 infection in patients stratified by oncological treatment To assess the possible relationship of the different oncological treatments administered to these patients with the clinical evolution of the COVID-19 infection. Complications will be classified by type and severity in groups of patients stratified by the oncological treatment received. Through study completion, average 1 year
Primary Frequency of adverse events related to immunotherapy targeted to cancer (classified by type and severity) To specifically assess the impact of COVID-19 infection on the toxicity of immunotherapy treatment (mainly pneumonitis) and the impact of immunotherapy on the evolution of the infectious picture in patients with tumors of genitourinary origin. three different scenarios: during treatment, after treatment and in patients who receive treatment after the infection has passed. Through study completion, average 1 year. Measured at 3 scenarios (during treatment, after treatment and therapies indicated after infection has passed)
Primary Frequency of complications of COVID-19 infection in patients with prostate cancer stratified by anti-androgenic oncological treatment To evaluate in patients with Prostate Cancer (PCa) the impact of androgen deprivation therapy (ADT) and new antiandrogenic agents (NAH) with or without corticosteroids on the infection COVID-19 as mean of frequency in complications of COVID-19 infection classified by type and severity Through study completion, average 1 year
Secondary COVID-19 mortality rate in patients with genitourinary cancer To assess the mortality associated with COVID-19 infection in the population with genitourinary tumors. Percentage of patients alive / dead at discharge. Through study completion, average 1 year
Secondary COVID-19 complication rate in patients with genitourinary cancer Evaluate the rate (percentage) of complications that have required hospital admission and / or ICU treatment. Complications will be classified by type and severity and represented as percentage of patients presenting them. Through study completion, average 1 year
Secondary Asymptomatic rate Describe the frequency of asymptomatic or minimally symptomatic COVID-19 infections. Through study completion, average 1 year
Secondary Frequency of delays/modifications on cancer treatment schedule delays / modifications in cancer follow-up or treatment regimens. The average delay time and the number of modifications will be evaluated. Through study completion, average 1 year
Secondary Progression free survival in patients with genitourinary tumors that suffered COVID-19 It is expected to obtain data on time to progression and overall survival of cancer patients, which can be compared with the reference values for each type of tumor pathology Through study completion, average 1 year
Secondary Overall survival in patients with genitourinary tumors that suffered COVID-19 It is expected to obtain data on time to progression and overall survival of cancer patients, which can be compared with the reference values for each type of tumor pathology Through study completion, average 1 year
See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Active, not recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3